Curbing Breast Cancer by Altering V-ATPase Action on F-Actin, Heterochromatin, ETV7 and mTORC2 Signaling

Zeina S Khan1, Fazle Hussain2

  • 1Department of Mechanical Engineering, Texas Tech University, 2703 7th Street, Lubbock, 79409, Texas, USA.

Abstract

Insights

Proton pump inhibition hinders breast cancer cell migration and proliferation by reducing F-actin polymerization and impacting AKT/mTOR signaling. These findings highlight vacuolar proton pumps as potential therapeutic targets for metastatic cancer.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Molecular Oncology

Background:

  • Vacuolar proton pumps play a critical role in cancer progression.
  • Investigating proton pump inhibition offers potential therapeutic strategies for breast cancer.

Purpose of the Study:

  • To examine the effects of proton pump inhibition on breast cancer cell migration and proliferation.
  • To analyze the impact on F-actin polymerization, lamin A/C, heterochromatin, ETV7 expression, nuclear characteristics, and AKT/mTOR signaling.

Main Methods:

  • Treatment of MCF7 and MDA-MB-231 breast cancer cells with Bafilomycin A1 (proton pump inhibitor).
  • Assessment of cell migration (wound-scratch assay), proliferation (cell area expansion), and ATP levels.
  • Quantification of F-actin, lamin A/C, heterochromatin, ETV7, and AKT/mTOR signaling components via immunocytochemistry and western blots.

Main Results:

  • Proton pump inhibition reduced F-actin polymerization, cell migration, and proliferation in both cell lines.
  • Inhibition increased heterochromatin and decreased lamin A/C, p-mTORC1, p-mTORC2, and mTOR levels.
  • Differential effects on ETV7 expression and p-AKT levels were observed between lowly and highly metastatic cells.

Conclusions:

  • Vacuolar proton pumps promote F-actin polymerization and invasion by decreasing heterochromatin.
  • These pumps upregulate mTORC1 and mTORC2 signaling pathways.
  • Vacuolar proton pumps represent a promising therapeutic target for inhibiting cancer metastasis.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K